The BNDX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BNDX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BNDX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View BNDX Detailed Price Forecast - CNN Money||View BNDX Detailed Summary - Google Finance|
|View BNDX Detailed Summary - Yahoo! Finance||View BNDX Stock Research & Analysis - Zacks.com|
|View BNDX Trends & Analysis - Trade-Ideas||View BNDX Major Holders - Barrons|
|View BNDX Call Transcripts - NASDAQ||View BNDX Breaking News & Analysis - Seeking Alpha|
|View BNDX Annual Report - CompanySpotlight.com||View BNDX OTC Short Report - OTCShortReport.com|
|View BNDX Fundamentals - TradeKing||View BNDX SEC Filings - Bar Chart|
|View Historical Prices for BNDX - The WSJ||View Performance/Total Return for BNDX - Morningstar|
|View the Analyst Estimates for BNDX - MarketWatch||View the Earnings History for BNDX - CNBC|
|View the BNDX Earnings - StockMarketWatch||View BNDX Buy or Sell Recommendations - MacroAxis|
|View the BNDX Bullish Patterns - American Bulls||View BNDX Short Pain Metrics - ShortPainBot.com|
|View BNDX Stock Mentions - StockTwits||View BNDX Stock Mentions - PennyStockTweets|
|View BNDX Stock Mentions - Twitter||View BNDX Investment Forum News - Investor Hub|
|View BNDX Stock Mentions - Yahoo! Message Board||View BNDX Stock Mentions - Seeking Alpha|
|View Insider Transactions for BNDX - SECform4.com||View Insider Transactions for BNDX - Insider Cow|
|View BNDX Major Holdings Summary - CNBC||View Insider Disclosure for BNDX - OTC Markets|
|View Insider Transactions for BNDX - Yahoo! Finance||View Institutional Holdings for BNDX - NASDAQ|
|View BNDX Stock Insight & Charts - FinViz.com||View BNDX Investment Charts - StockCharts.com|
|View BNDX Stock Overview & Charts - BarChart||View BNDX User Generated Charts - Trading View|
Vanguard Announces Plans To Launch Total World Bond ETF
Posted on Monday May 21, 2018
VALLEY FORGE, Pa., May 21, 2018 /PRNewswire/ -- Vanguard today filed a preliminary registration statement with the Securities and Exchange Commission for Vanguard Total World Bond ETF. The fund will be structured as an ETF of ETFs, investing directly in two existing low-cost ETFs: Vanguard Total Bond Market ETF (BND) and Vanguard Total International Bond ETF (BNDX). This structure enables the Vanguard Total World Bond ETF to achieve immediate scale by using existing exposure from the underlying ETFs and is expected to result in tighter bid/ask spreads and lower operating expenses than investing directly in the benchmark's constituents.
One Of This Top Asset-Gathering Bond ETFs Has Little US Debt
Posted on Thursday April 26, 2018
Year-to-date, three fixed income exchange-traded funds are among the top 10 ETFs in terms of new assets added. The iShares Short Treasury Bond ETF (NYSE: SHV ) and the iShares Core Aggregate Bond ETF (NYSE: ...
Global Bond ETF Investors Eye China Exposure
Posted on Friday March 23, 2018
Global bond ETF investors that track the benchmark Bloomberg Barclays Global Aggregate Index may soon have exposure to Chinese renminbi-denominated government and policy bank securities. Bloomberg announced ...
BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the U.S. with BiondVax's Universal Flu Vaccine
Posted on Monday November 20, 2017
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced the signing of the clinical trial agreement (CTA) for a Phase 2 clinical trial with the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH). The study is titled "A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity, and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Trivalent Influenza Vaccine." It is designed to evaluate the cell mediated immunity directly induced by BiondVax's universal flu vaccine candidate M-001, as well as M-001's priming effect to enhance the immunogenicity of current seasonal influenza vaccines.